Biopharma News : Biopharma and Pharma news from all around the world :
- Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 2025
- KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen
- Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer
- Salubris Biotherapeutics Announces Dose Escalation Data for JK06, a 5T4-Targeted Antibody Drug Conjugate, at the European Society for Medical Oncology 2025 Congress
- Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025
- Genentech’s Phase III evERA Data Showed Giredestrant Significantly Improved Progression-Free Survival in People With ER-Positive Advanced Breast Cancer
- Genentech Presents New Phase III Pivotal Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss
- TEZSPIRE approved in the US for chronic rhinosinusitis with nasal polyps
- Welldoc Expands AI-Powered Cardiometabolic Platform to Include Chronic Kidney Disease and MASH Support
- LucyRx Launches an Outcomes Accord, Uniting Consultants, Brokers and Employers to Raise PBM Accountability
- Oxford Nanopore Announces PromethION Plus Flow Cell and Human Genetics Updates at ASHG 2025
- New Surescripts First-Fill Abandonment Solution Empowers Providers with Insights to Help Improve Patient Care, Increase Medication Adherence and Advance Value-Based Care Performance
- Liberate Bio Demonstrates First In Vivo CAR-M–Mediated B-Cell Depletion in Non-Human Primates
- Hospital for Special Surgery and General Atlantic Launch National Platform to Expand Access to Orthopedic and Spine Outpatient Care
- ProteinQure Reports Broad Brain Distribution of Peptide-siRNA Conjugates in Non-Human Primates
- PeptiDream, PDRadiopharma and Curium Group Enroll First Patient to Registrational Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan
- Genentech Data at ESMO 2025 Showcase Advances in Science and Cancer Care Across Multiple Tumor Types
- AdvanCell to Present Promising Clinical Trial Results of ADVC001, a Novel Lead-212-based PSMA-targeted Alpha Therapy for Prostate Cancer, at ESMO 2025
- Natera to Present 14 Studies at ESMO, Including IMvigor011 Oral Presentation in Presidential Symposium
- Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric Study
- Data from Incyte’s TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 2025
- AHF Commends Gov. Newsom for Signing PBM Reform Bill (SB 41, Weiner)
- Bristol Myers Squibb and TV Host Gail Simmons Tackle Stigma in Schizophrenia with New Initiative Spotlighting the Power of Support and Connection
- Mundipharma announces patient enrolment completion in Phase III ReSPECT clinical trial for REZZAYO® (rezafungin)
- Data from GNT-018-IDES Trial Supports Feasibility of imlifidase as Pretreatment in Gene Therapy Treatment for Patients With Crigler–Najjar Syndrome Who Are Immune to AAV
- Data Analyses Show Benefit for Individuals With Infantile-Onset Niemann-Pick Disease Type C Treated With Investigational Drug Adrabetadex
- GE HealthCare unveils Carestation 850 at ANESTHESIOLOGY 2025: its next-generation anesthesia delivery system designed to adapt to care needs
- Merck Expands Tulisokibart Clinical Development Program With Initiation of Phase 2b Trials in Three Additional Immune-Mediated Inflammatory Diseases
- Within3 Names Ian McKinnon, Ph.D., as Managing Director, Global Head of Consulting
- Owlstone Medical Wins up to $49.1 Million Award from ARPA-H to Develop At-home Multi-Cancer-Early Detection Tests
News about Biotech, Pharma, Biopharma, Medical Devices, Diagnostics, Digital Health
- ActiTrexx completes treatment of last patient with novel regulatory T cell therapy against Graft-versus-Host Disease
- Pulsion Medical Systems SE: MAQUET Medical Systems AG increases the amount of the cash compensation for the transfer of the shares in Pulsion Medical Systems SE to be EUR 20,67
- M1 Kliniken AG: M1 Kliniken AG: HAEMATO AG sells its 100% subsidiary HAEMATO Pharm GmbH to PHOENIX group
- Actor Pharmaceuticals and Megalabs become partners for the commercialization of Formycon’s Eylea® biosimilar FYB203 (aflibercept) for Australia and Latin America
- Xlife Sciences AG Publishes 2024 ESG Report: Sustainable Value Creation as a Strategic Core
- DocMorris accelerates sequential Rx growth and increases non-Rx revenue
- Sartorius Stedim Biotech publishes unaudited results for the first nine months of 2025
- Drägerwerk AG & Co. KGaA: Preliminary figures Q3 2025: Significant increase in net sales and earnings – upper half of forecast range expected
- bonyf AG receives the EU-MDR Certification Class IIa for PerioCream
- Cabinet decision on the Medical Cannabis Act meets broad criticism / Cantourage expects changes and prepares to expand its “Telecan” platform
- QUANTRO Therapeutics extends collaboration with Boehringer Ingelheim to address high unmet needs in cancer patients
- Together We Build: Rentschler Biopharma celebrates construction progress of new buffer media facility, largest single investment at Laupheim site
- Gerresheimer: FDA grants Approval of SQ Innovation’s Lasix® ONYU*
- Biotest’s Yimmugo® launches in the United States
- SYNLAB expands investment in Italy with opening of flagship Medical Centre in Florence
- Heidelberg Pharma Reports on the First Nine Months of Financial Year 2025
- Gerresheimer: Business performance and slower market growth require guidance adjustment
- Gerresheimer AG: Business performance and slower market growth require adjustment of guidance for 2025
- Cantourage is responding to potential developments resulting from new legal regulations with focused internationalization and strategic product diversification
- Relief Therapeutics and NeuroX, Successor to MindMaze, Sign Definitive Agreement for Business Combination
- Heidelberg Pharma AG Announces Updated Guidance
- Pentixapharm Highlights Expanding CXCR4 Radiopharmaceutical Platform with New Clinical Findings at EANM 2025
- Invitation: Straumann Group 2025 third-quarter results webcast
- Lonza Nominates Claudia Süssmuth-Dyckerhoff as Board Member
- Positive Outlook: Cannabis Legalization Review and Trump’s Endorsement Send Encouraging Signals
- Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with Regeneron
- Newron to present new analyses from and updates on its clinical program evaluating evenamide as an add-on treatment for schizophrenia at the 38th ECNP Congress 2025
- Immunic to Participate in Scientific and Investor Conferences in October
- Gerresheimer Expands Wertheim Site with new Production Facility for Ready-to-fill Vials
- Viromed Medical AG drives forward market launch of new products in the first half of 2025 and expands strategic partnerships
- Noom Launches AI Face Scan and AI Future Me to Bring Preventive Health Insights to Everyone
- ThrIVe Health Announces Patient Education Seminar Featuring Leading Thyroid Eye Disease Specialist Dr. Raymond Douglas
- IMPALA Appoints Ann Marie Dunne as New Chair, Succeeding Jonathan Taylor
- KFSHRC Performs World’s First Robotic Intracranial Tumor Resection … A New Era in Neurosurgery
- KFSHRC Performs World’s First Robotic Intracranial Tumor Resection … A New Era in Neurosurgery
- Eleos to Launch Polaris AI Advanced, Purpose-Built Foundational AI Model for Post-Acute Care, built with Google Cloud Technology
- Eleos to Launch Polaris AI Advanced, Purpose-Built Foundational AI Model for Post-Acute Care, built with Google Cloud Technology
- ADARx Pharmaceuticals Announces Clinical Data Presentation at the American Society of Nephrology (ASN) Kidney Week 2025
- ADARx Pharmaceuticals Announces Clinical Data Presentation at the American Society of Nephrology (ASN) Kidney Week 2025
- VitalHub Announces Q3 2025 Conference Call Date
- VitalHub Announces Q3 2025 Conference Call Date
- Avance Clinical Launches Dedicated Center of Excellence to Accelerate Early Phase Biotech Trials
- Avance Clinical Launches Dedicated Center of Excellence to Accelerate Early Phase Biotech Trials
- AAMI and TechNation Collaborate to Survey HTM Field
- Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors
- Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors
- Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors
- Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors
- IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025
- IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025
- Pharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio
- Roche’s Tecentriq showed significant overall and disease-free survival benefits in bladder cancer with ctDNA-guided treatment
- FDA approves Roche’s Gazyva/Gazyvaro for the treatment of lupus nephritis
- Press Release: Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose
- Ryoncil® Net Revenues Increase 69% in Second Quarter Post Launch
- Subcutaneous RYBREVANT®▼(amivantamab) delivers promising 45 percent overall response rate with median duration of response of 7.2 months in recurrent or metastatic head and neck cancer
- PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer
- Avacta Therapeutics Presents Compelling Phase 1a Data for Faridoxorubicin and the pre|CISION® Platform at the European Society of Medical Oncology Annual Congress
- RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)
- Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025
Sources for this page of Biopharma News : biopharma-reporter.com and worldpharmanews and pharmatimes.com and drugs.com and fiercepharma.com and scripintelligence.com and PR Newswire and Business Wire. Please visit all this very interesting websites for more info.
Biopharma News – Pharma News